The table below shows NewAmsterdam Pharma Company N.V.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
Revenue
$22.50M
$45.56M
$14.09M
$102.69M
-
Cost of revenue
-
-
-
-
-
Gross profit
-
-
-
-
-
R&D
$141.83M
$151.41M
$159.42M
$86.74M
$28.97M
SG&A
$106.35M
$70.45M
$37.63M
$19.51M
$6.00M
NAMS annual revenue (10-K history)
NewAmsterdam Pharma Company N.V. reported annual revenue of $22.50M for fiscal year 2025. That is down 50.6% from $45.56M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.